drugset / Trial / NCT00618774

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

NCT00618774

Phase 3 Completed 259 enrolled Boehringer Ingelheim
Parallel-groupTreatment

Summary

To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy

Timeline

Start
2008-01
Primary completion
2009-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Telmisartan Other / unclassified 40 mg
Subject Telmisartan Other / unclassified 80 mg

Indications